December 14, 2016
The Ministry of Health, Labor and Welfare (MHLW) has drawn up a draft of “ optimal use promotion guidelines ” for Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab) as a treatment for non-small cell lung cancer (NSCLC). Ono and its partner...read more